AlphAIAlphAI — Financial news for AI agents
investing.comOCT 22 min read$FHTX

Guggenheim cuts Foghorn Therapeutics price target on drug setback

Guggenheim cut Foghorn Therapeutics' (FHTX) price target to $5.00 from $12.00, maintaining a Buy rating, after the company discontinued its lead drug program FHD-909. Foghorn and partner Eli Lilly halted the program due to insufficient efficacy in Phase 1 trials. The stock is down 16.6% over the past week, trading at $2.92. Analysts have mixed reactions, with some downgrading and others maintaining Buy ratings with adjusted targets.

Original reporting
investing.com
Published Oct 2, 2026, 11:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 11:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$FHTX
Bearish
high confidence
Mentioned
$FHTX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$FHTXBearishLow
01

Why it matters

The news triggered a price target reduction and a 16.6% drop in the stock over the past week, reflecting market disappointment.

02

Market read

The drug setback directly impacts FHTX valuation and may influence sentiment toward similar early‑stage oncology assets.

03

What to watch

Potential upside from the remaining pipeline, including EP300 degrader slated for 2027 IND.

Relevance 7/10Novelty 8/10Timing: today

Background

Foghorn Therapeutics announced the cessation of its partnership with Eli Lilly on the SMARCA2 inhibitor FHD-909 after Phase 1 data fell short of efficacy thresholds.

Company-level read

Ticker impact

$FHTXBearishHigh confidence
Context

Guggenheim cut its price target on Foghorn Therapeutics to $5.00 after the company halted its lead drug program FHD-909.

Expected impact

likely downward pressure as investors price in the clinical setback

Evidence & confidence

Analyst target cut and 16% weekly decline indicate market reaction to the drug halt.

Market effects

Sector

Biotech sector may see heightened scrutiny of SMARCA2 programs.

Regional

U.S. biotech investors likely adjust exposure.

Global

Limited to investors tracking early‑stage oncology pipelines.

Counterpoint

What could challenge this read

Some investors may view the reduced cash burn as a catalyst for a short‑term bounce.

Key entities

  • company
    Foghorn Therapeutics

    Biotech firm developing epigenetic therapies.

  • company
    Eli Lilly

    Pharmaceutical partner in the discontinued program.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 2
$FHTXMed

Wedbush cuts Foghorn Therapeutics stock rating on drug setback

Wedbush downgraded Foghorn Therapeutics (FHTX) to Neutral, lowering its price target to $2.00. The move follows the discontinuation of FHD-909, a drug in collaboration with Eli Lilly, due to Phase 1 data. Foghorn is cutting 40% of its workforce and realigning operations. Other analysts have also lowered price targets, though some maintain positive ratings.

investing.com2 min
OCT 1
$FHTXHigh

Citizens downgrades Foghorn Therapeutics stock rating on drug discontinuation

Citizens downgraded Foghorn Therapeutics (FHTX) to Market Perform after it and Eli Lilly discontinued the FHD-909 drug candidate due to poor efficacy. Shares fell 18% to $2.88, extending a 34% YTD decline. Citizens cited lack of near-term catalysts, noting shares trade at a 26% premium to cash reserves. InvestingPro analysis suggests undervaluation, while Stifel lowered its price target to $5.00 but maintained a Buy rating.

investing.com2 min
OCT 1
$FHTXHigh

Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal

Foghorn Therapeutics (FHTX) stock fell 27.17% after ending its collaboration with Eli Lilly (LLY) and halting development of FHD-909. The company will focus on its wholly owned pipeline, including an EP300 degrader, and expects cash runway to extend into 2H 2029. FHTX reported $167.6M in cash as of June 30, 2026.

aol.com1 min